Gilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market.
Marylyn Donahue
Advertisement
Articles by Marylyn Donahue
The Department of Veterans Affairs and other California panels’ solution to the new and extremely costly hepatitis (Hep) C drugs (Sovaldi and Olysio) is to reserve them for the patients with advanced liver diseases, including those awaiting transplants.
In response to the recent shooting at Fort Hood that killed four (including the killer’s suicide) and wounded 16, the mental health watchdog Citizens Commission on Human Rights (CCHR) views this and other recent incidents as a wake-up call to the dangers of antidepressants.
Advertisement
Latest Updated Articles
- High Price of Gilead's Sovaldi Could Deter Early Hep C Treatment
Published: April 23rd 2014 | Updated:
- Is Gilead’s $1000 Pill Worth It?
Published: April 20th 2014 | Updated:
- The Fort Hood Killing and Psychotropic Drugs
Published: April 7th 2014 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
2
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
3
GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate
4
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
5
